Nevertheless, further studies were validated not only because there were indications that a subset of patients with moderately severe COPD might have benefitted by oxygen supplementation but also ...
For patients with chronic obstructive pulmonary disease (COPD) with a history of exacerbations and a blood eosinophil count of at least 300 cells/µL, mepolizumab leads to a lower annualized rate of ...
Please provide your email address to receive an email when new articles are posted on . Across several subgroups, more patients receiving ensifentrine vs. placebo were classified as Transitional ...
Please provide your email address to receive an email when new articles are posted on . Unscheduled physician office visits, ED visits and unplanned hospitalizations made up the studied COPD-related ...
Certain glucose-lowering drugs were linked to fewer moderate or severe COPD exacerbations in adults with type 2 diabetes Study: Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary ...
Researchers found that the risk for moderate or severe COPD exacerbation was lower among those treated with SGLT-2is vs DPP-4is and among those treated with GLP-1 RAs vs DPP-4is. HealthDay News — For ...
"The evidence we have in persons with mild-to-moderate COPD, or who are minimally symptomatic, on reducing exacerbations and improving quality of life is still very limited." — Jennifer S. Lin, MD, ...
Patients who received fluticasone furoate-vilanterol had a 9% lower risk for a first moderate or severe COPD exacerbation than those who received budesonide-formoterol (hazard ratio [HR], 0.91; 95% CI ...
BARCELONA -- The need for antibiotics in patients with chronic obstructive pulmonary disease (COPD) seeking treatment for moderate acute COPD exacerbations could not be ruled out in a randomized trial ...
GSK announced today that Health Canada has approved Nucala (mepolizumab) as an add-on maintenance treatment in adult patients ...
GlobalData on MSN
Windward Bio doses first patients in Phase II SIRIUS COPD trial
The study aims to assess the safety, pharmacodynamics, pharmacokinetics and tolerability of HBM9378 for COPD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results